Literature DB >> 11579017

Addition of olanzapine for treatment-resistant depression.

W Pitchot, M Ansseau.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11579017     DOI： 10.1176/appi.ajp.158.10.1737-a

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN： 0002-953X            Impact factor:   18.112


× No keyword cloud information.
  5 in total

1.  An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression.

Authors:  Ashwin A Patkar; Kathleen Peindl; Rajnish Mago; Paolo Mannelli; Prakash S Masand
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2006

2.  Quetiapine fumarate augmentation for patients with a primary anxiety disorder or a mood disorder: a pilot study.

Authors:  Yi-Chih Chen; Chih-Ken Chen; Liang-Jen Wang
Journal:  BMC Psychiatry       Date:  2012-09-29       Impact factor: 3.630

3.  Combined venlafaxine and olanzapine prescription in women with psychotic major depression: a case series.

Authors:  Lucio Ghio; Werner Natta; Paola Rossi; Laura Peruzzo; Elisa Zanelli; Simona Gotelli; Filippo Gabrielli
Journal:  Case Rep Med       Date:  2011-04-04

4.  Off-label indications for atypical antipsychotics: A systematic review.

Authors:  Konstantinos N Fountoulakis; Ioannis Nimatoudis; Apostolos Iacovides; George Kaprinis
Journal:  Ann Gen Hosp Psychiatry       Date:  2004-02-18

5.  A review of quetiapine in combination with antidepressant therapy in patients with depression.

Authors:  Ella J Daly; Madhukar H Trivedi
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.